Cloning Breakthrough Highlights An Alternative Source For Stem Cells
CSIRO develops test to improve stem cell safety

Merck Has Solid Results in a Cancer Drug Trial

CHICAGO — An experimental drug from Merck that unleashes the body’s immune system significantly shrank tumors in 38 percent of patients with advanced melanoma, putting the company squarely in the race to bring to market one of what many experts view as the most promising class of drugs in years.

Full story.

Please visit our sponsor Gehrke & Associates, SC to learn more about how to enhance and defend your intellectual property.  Thank you.

Comments